Upcoming Conversation With An Expert: Preparing For More Phase 2 Data From Selecta Biosciences

Summary

We will be interviewing an academic rheumatologist familiar with SEL-212 (Selecta) and Horizon’s Krystexxa and has experience in managing chronic refractory gout.

This call will address the probability of success, especially in the high-dose cohort from the additional Phase 2 data for SEL-212 in chronic refractory gout.

This article will also provide a pre-call primer on Selecta Biosciences, their proprietary SVP platform, pout, and SEL-212.

By Slingshot intern Samuel Jordan

About Selecta Biosciences

Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company that is built around its proprietary synthetic vaccine particle (SVP) technology. The company focuses on developing therapies for rare diseases whose current treatments trigger dangerous immune responses in treated patients. Selecta creates treatments for these diseases that combine with its SVP technology to limit the occurrence of severe adverse effects. Its lead candidate, SEL-212, is a treatment for refractory gout that is like the current treatment, Krystexxa but avoids the drug’s potentially deadly adverse effects.

About SVP Platform

Selecta’s SVP Platform targets dendritic cells with nanoparticles designed to regulate the immune response. Once these immunomodulators are taken up by the cells they “deliver” a precise message to the patient’s immune system that can trigger or suppress its reaction to certain antigens. The SVP platform is combined with medications that are known to trigger an immune response averting the potential for an allergic reaction. The final element of the SVP platform is that it induces antigen-specific T-cells to spread throughout the body to prevent or encourage an immune response to continued antigen exposure.

About Gout

Gout is a common form of arthritis that is characterized by intense joint pain and inflammation. If left uncontrolled, it can lead to significant pain and joint damage in patients. The proximate cause of gout is a buildup of uric acid, in the form of urate crystals, in the joints. Ultimately, the disease is caused by a combination of lifestyle and genetic factors and is most common in overweight, middle-aged men with a family history of the disease. Refractory gout, the target of SEL-212, can lead to swelling and destruction of joints combined with recurring, debilitating attacks.

Reference

عضویت در کانال زیست فن☑

Upcoming Conversation With An Expert: Preparing For More Phase 2 Data From Selecta Biosciences

Rate this post
برچسب‌ها
نمایش بیشتر

نوشته‌های مشابه

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

همچنین ببینید

بستن
دکمه بازگشت به بالا
EnglishIran
بستن
بستن